| abstract |
(57) Abstract: An object of the present invention is to provide an anti-gp130 monoclonal antibody and use of the antibody for manufacturing a pharmaceutical, a cell culture adjuvant and a diagnostic reagent. SOLUTION: On April 12, 1995, accession number I C. at -1561. N. C. M. I-designated B-S12 produced by the hybridoma strain deposited at gG1 isotype monoclonal antibody and C.I. under the accession number I-1560 on April 12, 1995. N. C. M. Gp selected from the group consisting of the IgG1 isotype monoclonal antibodies designated B-P8 produced by the hybridoma strain deposited at Monoclonal antibody to the 130 receptor. I will provide a. |